<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>PMC</source>
  <date>20140719</date>
  <key>pmc.key</key>
  <document>
    <id>5109237</id>
    <passage>
      <infon key="name_2">surname:Fischer;given-names:Josephine</infon>
      <infon key="name_3">surname:Walter;given-names:Carolin</infon>
      <infon key="name_0">surname:Riemke;given-names:Pia</infon>
      <infon key="name_1">surname:Czeh;given-names:Melinda</infon>
      <infon key="name_6">surname:Agelopoulos;given-names:Konstantin</infon>
      <infon key="alt-title">Pia Riemke et&#160;al</infon>
      <infon key="article-id_publisher-id">EMBJ201693927</infon>
      <infon key="name_5">surname:Zepper;given-names:Matthias</infon>
      <infon key="name_8">surname:Gebhardt;given-names:Marie L</infon>
      <infon key="name_9">surname:Mah;given-names:Nancy</infon>
      <infon key="lpage">2416 2416</infon>
      <infon key="fpage">2399 2399</infon>
      <infon key="year">2016</infon>
      <infon key="kwd">leukemia lineage plasticity myeloid differentiation T&#8208;cell progenitors Cancer Development &amp; Differentiation Immunology</infon>
      <infon key="name_21">surname:Rosenbauer;given-names:Frank</infon>
      <infon key="name_20">surname:M&#252;ller&#8208;Tidow;given-names:Carsten</infon>
      <infon key="title">Subject Categories</infon>
      <infon key="article-id_doi">10.15252/embj.201693927</infon>
      <infon key="name_7">surname:Lettermann;given-names:Stephanie</infon>
      <infon key="source">The EMBO Journal</infon>
      <infon key="issue">22</infon>
      <infon key="name_4">surname:Ghani;given-names:Saeed</infon>
      <infon key="volume">35 35</infon>
      <infon key="article-id_pmc"/>
      <infon key="type">front</infon>
      <infon key="notes"> () : &#8211; See also:  L Bullinger (November 2016)</infon>
      <infon key="name_18">surname:Lenz;given-names:Georg</infon>
      <infon key="name_19">surname:Dugas;given-names:Martin</infon>
      <infon key="name_10">surname:Weilemann;given-names:Andre</infon>
      <infon key="name_11">surname:Grau;given-names:Michael</infon>
      <infon key="name_12">surname:Gr&#246;ning;given-names:Verena</infon>
      <infon key="name_13">surname:Haferlach;given-names:Torsten</infon>
      <infon key="name_14">surname:Lenze;given-names:Dido</infon>
      <infon key="name_15">surname:Delwel;given-names:Ruud</infon>
      <infon key="name_16">surname:Prinz;given-names:Marco</infon>
      <infon key="name_17">surname:Andrade&#8208;Navarro;given-names:Miguel A</infon>
      <offset>0</offset>
      <text>Myeloid leukemia with transdifferentiation plasticity developing from T&#8208;cell progenitors</text>
    </passage>
    <passage>
      <infon key="type">abstract_title_1</infon>
      <offset>91</offset>
      <text>Abstract</text>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>100</offset>
      <text>Unfavorable patient survival coincides with lineage plasticity observed in human acute leukemias. These cases are assumed to arise from hematopoietic stem cells, which have stable multipotent differentiation potential. However, here we report that plasticity in leukemia can result from instable lineage identity states inherited from differentiating progenitor cells. Using mice with enhanced c&#8208;Myc expression, we show, at the single&#8208;cell level, that T&#8208;lymphoid progenitors retain broad malignant lineage potential with a high capacity to differentiate into myeloid leukemia. These T&#8208;cell&#8208;derived myeloid blasts retain expression of a defined set of T&#8208;cell transcription factors, creating a lymphoid epigenetic memory that confers growth and propagates myeloid/T&#8208;lymphoid plasticity. Based on these characteristics, we identified a correlating human leukemia cohort and revealed targeting of Jak2/Stat3 signaling as a therapeutic possibility. Collectively, our study suggests the thymus as a source for myeloid leukemia and proposes leukemic plasticity as a driving mechanism. Moreover, our results reveal a pathway&#8208;directed therapy option against thymus&#8208;derived myeloid leukemogenesis and propose a model in which dynamic progenitor differentiation states shape unique neoplastic identities and therapy responses.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>1434</offset>
      <text>Introduction</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>1447</offset>
      <text>Acute leukemia (AL) refers to a heterogeneous group of blood cell disorders in which differentiation&#8208;blocked malignant myeloid or lymphoid cells expand uncontrolled. The treatment for AL depends on how the disease is classified according to both cytogenetic and phenotypic markers (Bene et&#160;al, 1995; Dohner et&#160;al, 2010). However, up to 20% of ALs remain difficult to classify, as they express both lymphoid and myeloid antigens (Matutes et&#160;al, 1997; Golemovic et&#160;al, 2006). Clinically, these &#8220;ambiguous&#8221; AL cases are highly relevant because they result in particularly poor patient survival and are frequently resistant to standard therapies (Golemovic et&#160;al, 2006; Coustan&#8208;Smith et&#160;al, 2009; Dorantes&#8208;Acosta &amp; Pelayo, 2012). In addition to lineage marker ambiguity, ALs that switch lineages in treatment&#8208;associated relapse have been described (Stass et&#160;al, 1984; Risueno et&#160;al, 2011). These findings imply that hematopoietic malignancies can hold immanent potential to differentiate into alternative lineages. While earlier studies have assumed that leukemias with lineage infidelity and switching capacity can arise upon malignant transformation of a hematopoietic stem cell (HSC; Matutes et&#160;al, 1997; Neumann et&#160;al, 2012), the underlying cellular origin of such lineage plasticity remains poorly defined.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>2777</offset>
      <text>One type of AL, acute myeloid leukemia (AML), is believed to originate from transformed HSCs or myeloid&#8208;restricted progenitors (Walter et&#160;al, 2012). However, these bone marrow (BM)&#8208;resident precursors are not the only cells with myeloid potential: myeloid potential has also been found in thymic CD4/CD8 double negative 1 (DN1) and 2 (DN2) cells, which represent the earliest stages of T&#8208;cell development (Bell &amp; Bhandoola, 2008; Wada et&#160;al, 2008). However, the contribution of DN1 and DN2 cells to physiological myelopoiesis in&#160;vivo has been questioned by lineage&#8208;tracing experiments (Schlenner et&#160;al, 2010). Nevertheless, the same authors found that approximately 15% of DN1 cells had robust myeloid differentiation capacity in&#160;vitro, confirming that thymic progenitors can produce myeloid progeny (Schlenner et&#160;al, 2010). In another study, myeloid potential was attributed to thymic progenitors in&#160;vivo, and early T cells were suggested as precursors of thymic granulocytes (De Obaldia et&#160;al, 2013). However, even if a contribution to myelopoiesis under homeostatic conditions is still unclear, these results demonstrated that the lymphoid fate of early T&#8208;cell progenitors is not yet fully stabilized and may compete with a residual option of myeloid differentiation. Therefore, we hypothesized that this myeloid potential may be exploited under pathological conditions so that T&#8208;cell precursors could transdifferentiate into leukemia with myeloid identity.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>4258</offset>
      <text>To test this hypothesis, we aimed to analyze the lineage potential of DN2 cells upon transformation. We reasoned that ectopic c&#8208;Myc (Myc) expression would serve our purpose best, as MYC has been demonstrated to transform cells, at least in part, by amplifying the expression of already transcribed genes without enforcing a lineage bias (Lin et&#160;al, 2012; Nie et&#160;al, 2012). Moreover, MYC is frequently overexpressed in both human acute myeloid and lymphoid leukemia (Majeti et&#160;al, 2009; Haferlach et&#160;al, 2010) (Appendix&#160;Fig S1A) and can rapidly induce hematopoietic neoplasias in mice (Luo et&#160;al, 2005). We therefore overexpressed Myc, together with Bcl2 to prevent apoptosis, in murine thymic and BM&#8208;resident precursor cells and compared their lineage potential in leukemogenesis.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>5049</offset>
      <text>Results</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>5057</offset>
      <text>Single DN2 cells possess malignant myeloid and T&#8208;lymphoid potential in&#160;vitro</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>5137</offset>
      <text>To evaluate the lineage potential of transformed T&#8208;cell precursors, we isolated DN2 cells from the thymus along with BM LSK cells (Lineage&#8722;Sca1+c&#8208;kit+ as a population enriched for HSCs) and granulocyte&#8211;macrophage progenitors (GMPs) from C57BL/6 CD45.2 donor wild&#8208;type mice. Cells were transduced with a retrovirus co&#8208;expressing Myc and Bcl2 from a bicistronic mRNA (Myc/Bcl2) (Appendix&#160;Fig S1B&#8211;D). From these populations, we sorted single cells into 96&#8208;well plates containing 1:1 mixtures of OP9:OP9&#8208;DL1 as feeder cell layers and analyzed the resulting clones via flow cytometry for the expression of CD11b and Gr1 as myeloid markers, and CD25 as an early T&#8208;lineage marker which was in line with previous reports (Bell &amp; Bhandoola, 2008; Wada et&#160;al, 2008). Myc/Bcl2&#8208;transduced DN2 cells generated immortalized clones with 8.6% plating efficiency, all of which had either mixed myeloid/T&#8208;cell or pure T&#8208;cell phenotypes (Fig&#160;1A and B). From the mixed&#8208;lineage clones, flow&#8208;sorted myeloid cells or lymphoid cells demonstrated typical blast&#8208;like myeloid or lymphoid morphologies, respectively, and produced short&#8208;latency leukemias in transplanted mice, indicating their fully transformed states (Fig&#160;1C). In contrast to DN2 cells, single Myc/Bcl2+ GMPs produced exclusively myeloid clones, and single Myc/Bcl2+ LSK cells produced predominantly pure myeloid clones but also mixed myeloid/T&#8208;cell and pure T&#8208;cell clones at lower frequencies (Fig&#160;1B and D). These results show that at the single&#8208;cell level, transformed DN2 cells do not exclusively produce T&#8208;lymphoid leukemia, but can also develop into myeloid leukemia.</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>6797</offset>
      <text>Single DN2 cells possess malignant myeloid and T&#8208;lymphoid potential</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>6867</offset>
      <text>Representative FACS plot (left) showing a mixed&#8208;lineage clone with a T&#8208;lymphoid (CD25+/CD11b&#8722;Gr1&#8722;), myeloid (CD11b+Gr1+/CD25&#8722;), and biphenotypic (CD11b+Gr1+/CD25+) fraction derived from a single Myc/Bcl2&#8208;transformed DN2 cell grown on 1:1 OP9:OP9&#8208;Dll1 co&#8208;culture with lineage&#8208;promiscuous cytokines IL&#8208;2, IL&#8208;3, IL&#8208;6, IL&#8208;7, SCF, GM&#8208;CSF, Flt3. Morphology of the indicated flow&#8208;sorted cell fractions was analyzed by Giemsa staining (right).</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>7333</offset>
      <text>Phenotype frequencies of clones from Myc/Bcl2&#8208;transformed single cells (grown and phenotyped as mentioned in A). Analyzed were 31 clones from LSKs, 107 from GMPs and 28 from DN2 cells.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>7520</offset>
      <text>Mice that received 5&#160;&#215;&#160;104 to 5&#160;&#215;&#160;105 T&#8208;lymphoid cells or myeloid cells flow&#8208;sorted from mixed Myc/Bcl2+ DN2&#8208;derived clones showed a cumulative survival of 31&#160;&#177;&#160;2 and 27&#160;&#177;&#160;6 days respectively. The summarized data are from three mice injected with the T&#8208;lymphoid and four mice injected with the myeloid fraction of two different clones.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>7876</offset>
      <text>Representative FACS plots demonstrating predominant outgrowth of myeloid clones from single Myc/Bcl2&#8208;transformed LSK or GMP cells on OP9:OP9&#8208;Dll1 co&#8208;cultures.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>8041</offset>
      <text>(top panels) Serial replating of Myc&#8208;Bcl2+ DN2 cells in methylcellulose generated myeloid clones with stable genomic reassembly of the D&#946;1 TCR locus in&#160;vitro (gel: left two lanes). Upon transplantation, the same clones induced myeloid leukemia that retained the initial rearrangement in&#160;vivo (gel: right two lanes) as assessed by nested PCR. GL&#160;=&#160;germline. (bottom panels) Methylcellulose&#8208;based replating of Myc&#8208;Bcl2+ GMPs generated myeloid clones that exclusively displayed the TCR&#946; locus in germline configuration.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>8570</offset>
      <text>Cumulative survival of mice that received 106 cells of TCR&#946;&#8208;rearranged myeloid DN2&#8208;derived clones leading to death 33&#160;&#177;&#160;4&#160;days after transplantation. Two DN2 clones were transplanted into five recipient mice.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>8788</offset>
      <text>The myeloid potential of DN2 cells was stable across the leukemia transforming event, as transduction with the MLL&#8208;AF9 [t(9;11)] oncogenic fusion also generated mixed myeloid/T&#8208;cell clones at high frequency (Appendix&#160;Fig S2A and B). This suggests that the potential to produce myeloid blasts represents a feature that is endogenous to transformed DN2 cells.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>9151</offset>
      <text>DN2 cells with T&#8208;cell receptor rearrangement can generate myeloid leukemic progeny</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>9236</offset>
      <text>The defining step in T&#8208;cell development is rearrangement of the T&#8208;cell receptor (TCR) locus. Thus, to underscore that T&#8208;cell progenitors can transform into myeloid blasts, we first identified rearrangement of the TCR beta locus in Myc/Bcl2+ DN2&#8208; and DN1&#8208;derived myeloid clones (Appendix&#160;Fig S2C) and subsequently transplanted one of each into mice. In both cases, the donor cells rapidly produced lethal myeloid leukemias, in which the blasts carried the same rearrangements as the initial clones (Fig&#160;1E and&#160;F and data not shown). This experiment provides genetic&#160;evidence that myeloid leukemia can originate from T&#8208;cell progenitors.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>9887</offset>
      <text>Transformed DN2 cells give rise to leukemias with clonal myeloid and T&#8208;lymphoid populations in&#160;vivo</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>9990</offset>
      <text>To directly assess the leukemic lineage potential in&#160;vivo, we first transduced DN2 cells with Myc/Bcl2 and then immediately transplanted them intravenously into sublethally irradiated congenic mice. In line with the in&#160;vitro results, Myc/Bcl2+ DN2 cells produced leukemias consisting of myeloid, T&#8208;cell, and biphenotypic fractions in the same recipients (Fig&#160;2A). We also did this for Myc/Bcl2+ LSK cells, which also produced mixed&#8208;lineage leukemia, but with reduced T&#8208;lymphoid and biphenotypic fractions. The Myc/Bcl2+ GMPs exclusively produced myeloid leukemia. We also generated Myc/Bcl2+ DN3 cells, representing a more differentiated T&#8208;cell progenitor, which produced exclusively T&#8208;lymphoid leukemia, in part with dim co&#8208;expression of myeloid markers, but never myeloid leukemia (Appendix&#160;Fig S3A).</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>10809</offset>
      <text>Myc/Bcl2+DN2 cells give rise to clonal myeloid and T&#8208;lymphoid leukemia in&#160;vivo</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>10891</offset>
      <text>Representative FACS plots of spleens from leukemic recipient mice that had received LSK, GMP, or DN2 cell grafts immediately after retroviral Myc/Bcl2 transduction. Numbers indicate frequencies (%) of CD45.2 donor cells within the indicated gates summarizing the mean&#160;&#177;&#160;SEM of at least eight recipients per group from a total of 10 independent experiments.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>11251</offset>
      <text>Cumulative survival of mice that received 2&#160;&#215;&#160;104 to 2&#160;&#215;&#160;105 freshly Myc/Bcl2&#8208;transduced LSK, GMP, or DN2 cells. Graph shows n&#160;=&#160;11 Myc&#8208;Bcl2+ LSK&#8208;, n&#160;=&#160;14 DN2&#8208;, and n&#160;=&#160;8 GMP&#8208;transplanted animals.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>11470</offset>
      <text>Histological spleen sections of Myc&#8208;Bcl2+ LSK&#8208;, GMP&#8208;, or DN2&#8208;transplanted mice displaying myeloperoxidase staining. Leukemic cell engraftment in spleens ranged from 75.1% to 95.5%.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>11659</offset>
      <text>Multiplex quantitative RT&#8211;PCR demonstrating strong expression of PU.1 in the myeloid (M3L: CD11b+Gr1+/CD3&#8722;CD4&#8722;CD8&#8722;) and biphenotypic T/myeloid (BL: CD11b+Gr1+/CD3+CD4+CD8+) fractions but not in the T&#8208;lymphoid (TL: CD11b&#8722;Gr1&#8722;/CD3+CD4+CD8+) fraction that were flow&#8208;sorted from diseased Myc&#8208;Bcl2+ DN2&#8208;transplanted mice. Myeloid progeny of Myc/Bcl2+ GMP&#8208;transplanted or T&#8208;lymphoid progeny of Myc/Bcl2+ DN3&#8208;transplanted animals as well as healthy thymocytes (Thy) and BM cells from WT mice served as controls. Results are shown as fold over actin transcripts. Error bars define standard deviation (SD), number of replicates n&#160;=&#160;2.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>12313</offset>
      <text>D&#8208;J rearrangement PCR of flow&#8208;sorted T&#8208;lymphoid (TL), biphenotypic (BL) and myeloid (ML) fractions of donor splenocytes of a diseased Myc/Bcl2+ DN2&#8208;transplanted mouse. All three fractions revealed a stable genomic reassembly of the D&#946;1 TCR locus (D&#946;1J&#946;1.5) demonstrating clonality in DN2 leukemia. thy&#160;=&#160;thymus.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>12638</offset>
      <text>FACS plot of diseased intrathymic grafts (CD45.2&#8208;gated), demonstrating that Myc/Bcl2+ DN2 cells could produce multi&#8208;lineage leukemia within a T&#8208;cell&#8208;supporting environment; Myc/Bcl2+ GMPs remained myeloid&#8208;restricted under these conditions. Numbers indicate cell frequencies within the gates (mean&#160;&#177;&#160;SEM) representing six independent experiments.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>12997</offset>
      <text>Intrathymic transplantation of mock&#8208;infected non&#8208;leukemic DN2 cells produced predominantly T&#8208;lymphoid but also myeloid progeny 23&#160;days after injection. This differentiation outcome resembles that of freshly isolated DN2 cells (Bell &amp; Bhandoola, 2008; Richie Ehrlich et&#160;al, 2011) and indicates that the short&#8208;term culture necessary for retroviral transduction did not interfere with the physiological lineage potential of DN2 cells. </text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>13440</offset>
      <text>The mean survival of Myc/Bcl2+ DN2, LSK and GMP recipients was comparably short (56&#160;&#177;&#160;5, 39&#160;&#177;&#160;5 and 49&#160;&#177;&#160;4&#160;days, respectively) (Fig&#160;2B). The animals showed massive infiltration of the BM with myeloid blasts, leukocytosis, infiltration of lymphatic tissues (splenomegaly, lymphadenopathy), and indications of extralympathic infiltration (hind limb paralysis). In many mice, we observed elevated white blood cell counts (&gt;&#160;50&#160;&#215;&#160;103/&#956;l as compared to 9.2&#160;&#177;&#160;2.4&#160;&#215;&#160;103/&#956;l in healthy animals; data not shown). A detailed flow&#8208;cytometric characterization of Myc/Bcl2+ DN2&#8208;leukemia is given in Appendix&#160;Fig S3B and C. This revealed heterogeneous marker expression in the biphenotypic population. The myeloid population expressed both Gr1 and/or CD11b, as well as myeloperoxidase and PU.1, a key myeloid identity transcription factor that is not expressed in T cells (Rothenberg et&#160;al, 2008; Fig&#160;2C and D, and Appendix&#160;Fig S3B&#8211;F). Notably, TCR rearrangement analyses demonstrated clonal relationships between the T&#8208;lymphoid, biphenotypic, and myeloid fractions in leukemic Myc/Bcl2+ DN2&#8208;recipient mice (Fig&#160;2E), suggesting that single DN2 cells have multi&#8208;lineage potential in&#160;vivo.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>14655</offset>
      <text>To exclude the possibility that the short&#8208;term cultivation required for retroviral transduction imposed a myeloid lineage bias on DN2 cells, we showed that the in&#160;vivo differentiation capacity of mock virus&#8208;transduced cells was similar to that of DN2 cells freshly isolated from the thymus (Fig&#160;2G; Richie Ehrlich et&#160;al, 2011). Moreover, to more closely model the physiological transformation process in&#160;vivo, we also transplanted Myc/Bcl2+ DN2 cells directly into the thymus, and confirmed their myeloid leukemic potential (Fig&#160;2F). Intrathymic Myc/Bcl2+ DN2&#8208; or GMP&#8208;grafts developed full&#8208;blown leukemia after 36&#160;&#177;&#160;2 and 46&#160;&#177;&#160;5&#160;days, respectively (Appendix&#160;Fig S3G).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>15346</offset>
      <text>When comparing cell engraftment in BM, spleen, and thymus, we found that DN2&#8208; and GMP&#8208;derived blasts disseminated differently. Myc/Bcl2+ cells from GMPs preferentially infiltrated the organ(s) associated with their site of transplantation. Intravenously transplanted GMP&#8208;derived blasts primarily infiltrated the BM and spleen rather than the thymus (Appendix&#160;Fig&#160;S3H), while intrathymically transplanted GMP&#8208;derived blasts mainly stayed within the thymus. In contrast, Myc/Bcl2+ DN2&#8208;derived blasts infiltrated equally into all organs, suggesting an enhanced dissemination capacity.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>15940</offset>
      <text>DN2&#8208;myeloid blasts have DC&#8208;like identity and retain a cell&#8208;of&#8208;origin memory</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>16024</offset>
      <text>To determine the molecular mechanisms that drive development of myeloid blasts from DN2 cells, we performed gene expression profiling of flow&#8208;sorted myeloid fractions of Myc/Bcl2+ DN2&#8208;, LSK&#8208; and GMP&#8208;derived leukemias from sick mice, along with normal DN2 und GMP cells from healthy wild&#8208;type (WT) mice (Dataset&#160;EV1). To better disclose the lineage identity of the diseased cells, we used gene set enrichment analysis (GSEA) to compare transcriptomes of the flow&#8208;sorted myeloid fractions to gene signatures defining different myeloid cell populations (Schonheit et&#160;al, 2013). Whereas the GMP&#8208; and LSK&#8208;derived myeloid blasts mainly demonstrated a neutrophil identity, DN2&#8208;derived myeloid blasts exhibited a pan&#8208;dendritic cell (DC) signature (Fig&#160;3A), a finding confirmed with another DC signature (Chan et&#160;al, 2006; data not shown). This was in line with residual DC potential that has been assigned to early T&#8208;cell progenitors (Moore et&#160;al, 2012).</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>16998</offset>
      <text>DN2&#8208;myeloid leukemia retains a T&#8208;cell memory</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>17047</offset>
      <text>GSEA demonstrates that Myc/Bcl2+ DN2&#8208;derived myeloid blasts were significantly (FDR &#8805;&#160;0.05) enriched for expression of a pan&#8208;dendritic cell gene set. Gene sets were published in Schonheit et&#160;al (2013).</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>17257</offset>
      <text>Heat map of the top 100 differentially expressed genes (adjusted P&#8208;value of &#8804;&#160;0.05) in each myeloid fraction (ML: CD11b+Gr1+/CD3&#8722;CD4&#8722;CD8&#8722;) from GMP&#8208;, LSK&#8208;, and DN2&#8208;derived leukemias.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>17457</offset>
      <text>Dendrogram revealing transcriptional relationships between Myc/Bcl2+ DN2&#8208;, LSK&#8208;, and GMP&#8208;derived myeloid blasts based on unsupervised hierarchical clustering of all probes on the microarray.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>17654</offset>
      <text>GSEA demonstrates significant enrichment of a normal DN2&#8208;specific gene set (see Materials and Methods section) in the Myc/Bcl2+ DN2&#8208;derived myeloid blasts.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>17814</offset>
      <text>Through a heat map comparison of the top 100 genes most differentially expressed (P&#160;&#8804;&#160;0.05) in each of the analyzed cell populations, we revealed that DN2&#8208; and GMP&#8208;derived myeloid blasts clearly differed from each other, but LSK&#8208;derived blasts had an intermediate phenotype (Fig&#160;3B and Dataset EV2). Yet, unsupervised hierarchical clustering across the entire transcriptomes revealed that LSK&#8208; and GMP&#8208;derived cells are more closely related to each other than they are to DN2&#8208;derived cells (Fig&#160;3C). Moreover, GSEA demonstrated that a signature of genes highly expressed in WT DN2 cells was significantly enriched in the DN2&#8208; but not in GMP&#8208; or LSK&#8208;derived myeloid blasts (Fig&#160;3D and Dataset EV3). Collectively, gene expression profiling revealed that DN2&#8208;leukemia adopts a unique myeloid lineage identity, and still retains expression of a memory of its pre&#8208;malignant T&#8208;cell origin.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>18729</offset>
      <text>The T&#8208;cell memory is required for DN2&#8208;leukemia growth</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>18787</offset>
      <text>We next assessed if the T&#8208;cell memory was involved in driving Myc/Bcl2+ DN2&#8208;leukemia. Because cell&#8208;specific gene programs are mainly regulated by transcription factors (Rosenbauer &amp; Tenen, 2007; Rothenberg et&#160;al, 2008), we searched for genes in the thymic memory that encode transcription factors and identified Bcl11b and Gata3 as two promising candidates (Sambandam et&#160;al, 2005; Rothenberg, 2012). We confirmed expression of both proteins in DN2&#8208;derived leukemia, including the myeloid and biphenotypic fractions (Fig&#160;4A and Appendix&#160;Fig S4A and B), and generated a series of lentiviral constructs expressing different shRNAs to silence either factor (Appendix&#160;Fig S4C and D). Indeed, knocking down Bcl11b or Gata3 impaired growth of DN2&#8208; but not GMP&#8208;derived leukemia in culture, and completely abolished DN2&#8208;leukemic development in transplanted animals (Fig&#160;4B&#8211;D). Because both factors are important for normal T cells but not myeloid cells, we flow&#8208;sorted the DN2&#8208;derived biphenotypic and myeloid fractions and individually transduced them with the lentiviral shRNA constructs, revealing that both fractions required Bcl11b and Gata3 for growth&#160;(Appendix&#160;Fig&#160;S4E). These experiments suggest that DN2&#8208;leukemogenesis requires the T&#8208;cell memory.</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>20067</offset>
      <text>Bcl11b and Gata3 are required for DN2&#8208;leukemia</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>20116</offset>
      <text>Western blot illustrating abundant Bcl11b and Gata3 protein expression in Myc/Bcl2+ DN2&#8208; but not LSK&#8208; or GMP&#8208;derived blasts. Thymus (Thy) and bone&#160;marrow (BM) extracts from healthy WT mice served as controls. Detection of &#945;&#8208;tubulin or valosin&#8208;containing protein (VCP) ensured comparable loading.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>20424</offset>
      <text>Proliferation assays illustrating growth of Myc/Bcl2+ DN2&#8208; (B) or GMP&#8208;derived (C) blasts after lentiviral transduction with the indicated shRNAs. The shRNA&#8208;transduced cells were flow&#8208;sorted based on co&#8208;expression of the RFP reporter and seeded on OP9/OP9&#8208;Dll1 1:1 layers. Growing cells were RFP sorted for three rounds within 21&#160;days of culture and percent growth was calculated over the initially seeded cell number in relation to the Luc control. Shown are results of four independent experiments with cells from four different DN2&#8208; and three different GMP&#8208;leukemic animals. Luc&#160;=&#160;control shRNA targeting luciferase (Suzuki et&#160;al, 2003). At least two different shRNAs were used against Bcl11b or Gata3 as indicated. *P&#160;&#8804;&#160;0.05, Student's t&#8208;test. Error bars define SEM.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>21220</offset>
      <text>Representative FACS plots showing CD45.2&#8208;donor splenocytes of a secondary (CD45.1) recipient 23&#160;weeks after transplantation with 4&#160;&#215;&#160;103 RFP+Myc&#8208;Bcl2+ DN2&#8208;leukemia blasts carrying the indicated shRNAs. Luc: luciferase control shRNA. The data are representative of 2 Gata3, 4 Bcl11b, and 2 luciferase shRNA&#8208;transplanted animals. </text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>21561</offset>
      <text>Lineage plasticity of DN2&#8208;leukemia</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>21598</offset>
      <text>While leukemias with enhanced lineage plasticity have not yet been linked to a distinct cell&#8208;of&#8208;origin, a good candidate is stem cells (Cheng et&#160;al, 1986; Dorantes&#8208;Acosta &amp; Pelayo, 2012). However, because we identified a T&#8208;cell memory in the DN2&#8208;derived myeloid blasts, we hypothesized that they may harbor myeloid/T&#8208;lymphoid infidelity. To test this, we flow&#8208;sorted the myeloid fractions of Myc/Bcl2+ LSK&#8208;, DN2&#8208;, or GMP&#8208;derived leukemias established in primary mice and performed transplantation assays into secondary recipients. Whereas the GMP&#8208;derived blasts remained exclusively myeloid, indicating a complete lack of plasticity, those originating from LSKs converted into a biphenotypic population which in some mice was accompanied by a myeloid fraction (Fig&#160;5A and B). However, the LSK&#8208;derived myeloid blasts did not adopt a pure T&#8208;lymphoid phenotype, indicating incomplete plasticity. In contrast, only DN2&#8208;derived blasts were able to completely convert from the myeloid into a T&#8208;lymphoid phenotype in&#160;vivo. We next sorted single myeloid blasts from DN2&#8208;leukemic mice onto OP9:OP9&#8208;DL1 stromal cells, and confirmed their potential to switch phenotype at the clonal level (Fig&#160;5C). Intriguingly, not all clones possessed plasticity to the same extent (Fig&#160;5D), suggesting that the cells in the myeloid fraction had differential lineage potential.</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>22990</offset>
      <text>Enhanced plasticity of DN2&#8208;derived myeloid leukemia depends on dynamic PU.1 expression</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>23079</offset>
      <text>Representative FACS plots of splenocytes from diseased secondary recipients that were transplanted with 104 to 105 flow&#8208;sorted myeloid leukemia blasts (ML: CD11b+Gr1+/CD3&#8722;CD4&#8722;CD8&#8722;) from sick primary Myc/Bcl2+ LSK&#8208;, GMP&#8208;, or DN2&#8208;transplanted mice. Cell percentages in indicated gates are shown.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>23387</offset>
      <text>Table&#160;summarizing the phenotype frequencies within the spleens of secondary recipients that were retransplanted with Myc/Bcl2+ LSK&#8208;, GMP&#8208;, or DN2&#8208;derived myeloid blasts as described in (A). T&#8208;lymphoid leukemia: (TL: CD11b&#8722;Gr1&#8722;/CD3+CD4+CD8+), biphenotypic leukemia: BL (CD11b+Gr1+/CD3+CD4+CD8+), myeloid leukemia: ML (CD11b+Gr1+/CD3&#8722;CD4&#8722;CD8&#8722;). Numbers before the dash represent mice holding the indicated leukemia fraction; numbers after the dash indicate the total mouse count analyzed.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>23893</offset>
      <text>Single myeloid blasts from four different Myc/Bcl2+ DN2&#8208;derived leukemias were flow&#8208;sorted from transplanted mice and grown on irradiated OP9:OP9&#8208;DL1 stroma. The clones were analyzed at two different time points. FACS plots of two representative clones, one with strong (top), and one with weak (bottom) lineage switching potential are shown.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>24242</offset>
      <text>Table&#160;summarizing the lineage switching outcome of 20 independent clones that were grown from single DN2&#8208;derived myeloid blasts of four different leukemias. Percentages at the right indicate the relative amounts of cells with T&#8208;lymphoid (TL), biphenotypic (BL), or myeloid (ML) phenotype as analyzed by FACS at the end of the experiment.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>24585</offset>
      <text>FACS plot of DN2&#8208;derived primary leukemic cells transduced with a retrovirus carrying GFP alone or GFP together with PU.1 as a bicistronic RNA. The transduced cells were grown on OP9/OP9&#8208;Dll1 1:1 layer for 8&#8211;13&#160;days and analyzed using a GFP gate. The data are representative of 3 different experiments with similar outcome.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>24916</offset>
      <text>We also assessed plasticity of the T&#8208;lymphoid and biphenotypic populations from Myc/Bcl2+ LSK&#8208; and DN2&#8208;derived leukemias upon transplantation into secondary recipients; we found comparable abilities to switch between T&#8208;lymphoid and biphenotypic states, but low abilities to adopt the myeloid phenotype (Appendix&#160;Fig S5A). Taken together, these experiments demonstrate significant plasticity in both LSK&#8208; and DN2&#8208;derived leukemias and reveal a unique lineage switching capacity especially in the DN2&#8208;derived myeloid leukemia population.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>25467</offset>
      <text>PU.1 expression can determine plasticity in DN2&#8208;leukemia</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>25526</offset>
      <text>PU.1 strongly regulates myeloid gene expression (Rosenbauer &amp; Tenen, 2007) and is expressed in the myeloid and biphenotypic but not T&#8208;lymphoid fraction of DN2&#8208;leukemia (Fig&#160;2D). To test whether dynamic PU.1 expression determines lineage conversion of Myc/Bcl2+ DN2 cells, we transduced DN2&#8208;leukemia bulks from sick mice&#160;with a retrovirus coexpressing PU.1 and GFP and analyzed lineage distribution in culture. While control virus&#8208;transduced cells predominantly gave rise to progeny with T&#8208;lymphoid markers, PU.1&#8208;expressing cells produced mainly myeloid or biphenotypic progeny (Fig&#160;5E). Next, we transduced flow&#8208;sorted T&#8208;lymphoid cells from DN2&#8208;derived leukemias with the PU.1&#8208;expressing retroviruses. After just 4&#160;days, forced PU.1 expression reprogrammed most of them into biphenotypic or, to a lesser extent, myeloid blasts (Appendix Fig S5B), suggesting that dynamic PU.1 expression may dictate lineage outcome in DN2&#8208;derived leukemia.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>26492</offset>
      <text>DN2&#8208;leukemia is distinct from human ETP&#8208;ALL</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>26540</offset>
      <text>We next set out to identify a human disease that may correlate with murine DN2&#8208;leukemia. Comparison of orthologous gene expression has recently been used to define a novel human T&#8208;cell acute lymphoblastic leukemia (T&#8208;ALL) that shows co&#8208;expression of myeloid and stem cell markers (Coustan&#8208;Smith et&#160;al, 2009). Based on gene expression similarity with murine early T&#8208;cell precursors (ETP), representing a DN1 subpopulation, this disease has been speculated to originate from ETPs and was congruently termed ETP&#8208;ALL (Neumann et&#160;al, 2012). Thus, using GSEA, we tested whether murine DN2&#8208;leukemia corresponds to human ETP&#8208;ALL; however, we detected a negative correlation between both leukemia types using two independently published ETP&#8208;ALL gene expression signatures (Appendix&#160;Fig&#160;S6A and B).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>27353</offset>
      <text>A cohort of immature human AML cases resembles mouse DN2&#8208;leukemia</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>27421</offset>
      <text>To determine a possible human counterpart of mouse DN2&#8208;leukemia, we conducted an exploratory search concentrating on myeloid entities (AMLs). We used the set of the top 100 up&#8208; and downregulated genes (P&#160;&#8804;&#160;0.05) in the analyzed myeloid blasts from our mouse model, and compared it to the transcriptomes of 542 human AML samples (Haferlach et&#160;al, 2010). Indeed, the DN2&#8208;derived myeloid leukemia gene signature was similar to 26 samples (frequency: 4.8%) as assessed via a Spearman's rank correlation coefficient higher than 0.5 (Fig&#160;6A and Dataset EV4). A bootstrapping approach (see Materials and Methods) yielded a highly significant enrichment value (P&#160;=&#160;0.006) of the mouse DN2&#8208;leukemia signature in the human samples, thus confirming a non&#8208;random correlation. All DN2&#8208;like human AML samples of which metadata were available (8 of the 26 patients) had an immature phenotype, as evident from their French&#8208;American&#8208;British (FAB) classification as M0 (2 patients), M1 (1 patient), or M2 subtypes (5 patients), whereas the whole cohort consisted of M0&#8208;M6 patients (Dataset EV5).</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>28525</offset>
      <text>A cohort of immature human AML patients resembles mouse DN2&#8208;leukemia</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>28596</offset>
      <text>Heat map depicting all human AML samples from the Haferlach study (Haferlach et&#160;al, 2010) whose transcriptomes resembled DN2&#8208;leukemia by a Spearman's rank correlation coefficient &#8805;&#160;0.5. The top 100 up&#8208; and downregulated gene signature of Myc/Bcl2+ DN2&#8208;derived myeloid blasts was applied (see also Fig&#160;3B).</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>28913</offset>
      <text>Hierarchical clustering of all FAB M2 AML samples from the Verhaak study (Verhaak et&#160;al, 2009) based of the Myc/Bcl2+ DN2&#8208;derived myeloid blast top 100 upregulated (UP) gene signature (see Fig&#160;3B).</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>29115</offset>
      <text>GSEA confirming enrichment of the Myc/Bcl2+ DN2&#8208;derived myeloid blast top 100 UP (C) and pan&#8208;DC (Schonheit et&#160;al, 2013) (E) gene signatures in the human FAB M2 DN2&#8208;like AML samples as compared to all residual M2 AMLs from the Verhaak study (Verhaak et&#160;al, 2009). (D) Relative transcript levels of the T&#8208;cell receptor alpha locus (TRAC) in human DN2&#8208;like M2 AML compared to residual M2 AML patient samples from the Verhaak study (Wilcoxon rank&#8208;sum test, **P&#160;&#8804;&#160;0.01). Boxes represent 25&#8211;75% quantiles, whiskers represent minimum and maximum values.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>29682</offset>
      <text>We next validated this finding using a second human AML dataset (Verhaak et&#160;al, 2009) as it contained metadata for all patients, and focused on the FAB M2 subtype to achieve higher comparability within the samples. We identified nine M2 AMLs resembling the murine DN2&#8208;leukemia, which clustered together and were significantly enriched for the mouse DN2&#8208;myeloid leukemia signature (Fig&#160;6B and C). Their mutational spectrum resembled that of other AMLs (Appendix&#160;Fig S7A and Dataset EV4). Moreover, the DN2&#8208;like M2 AML patients expressed significantly more GATA3 and BCL11B as well as T&#8208;cell receptor alpha (TRAC) transcripts, but had unchanged MYC levels (Fig&#160;6D and Appendix&#160;Fig S7B and C). They also had DC&#8208;like transcriptional identity (Fig&#160;6E). Collectively, transcriptome comparisons identified a potentially novel cohort of immature human AMLs that resembles mouse DN2&#8208;derived leukemia.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>30592</offset>
      <text>DN2&#8208;leukemia is refractory to standard AML therapeutic agents</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>30656</offset>
      <text>Because lineage plasticity represents a possible non&#8208;mutational mechanism for cancer cells to escape therapy (Glickman &amp; Sawyers, 2012), we used our mouse model to test if Myc/Bcl2+ DN2&#8208;derived blasts would be refractory to standard AML drugs (Estey, 2009). Indeed, compared to their GMP&#8208;derived counterparts, DN2&#8208;derived cells were significantly less sensitive to the anthracyclines daunorubicin and doxorubicin in&#160;vitro (Fig&#160;7A).</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>31098</offset>
      <text>A targeted shRNA in&#160;vivo screen reveals requirements of Jak2/Stat3 signaling in DN2&#8208;leukemia</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>31194</offset>
      <text>Survival assay of Myc/Bcl2+ GMP&#8208; and DN2&#8208;derived leukemia cells that were isolated from diseased mice and treated for 24&#160;h with 0.15&#160;&#956;M daunorubicin or 1&#160;&#956;M doxorubicin in liquid culture. Cell death was measured by FACS of 7&#8208;AAD+ cells and was normalized to the solvent controls. The graphs show the mean+SEM of three different DN2&#8208; and five GMP&#8208;leukemias. **P&#160;&#8804;&#160;0.01, two&#8208;tailed Student's t&#8208;test.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>31615</offset>
      <text>Experimental procedure of the shRNA library in&#160;vivo screen. Blasts from leukemic mice that were transplanted with Myc/Bcl2+ DN2&#8208;cells were infected with a retroviral shRNA library consisting of &#732;300 GFP&#8208; or YFP&#8208;tagged shRNAs targeting a total of 142 different genes. Cells were harvested 72 h postinfection, the GFP+ and YFP+ fractions were flow&#8208;sorted, and 6&#160;&#215;&#160;104 cells were transplanted into secondary recipients. The residual cells were expanded for five days on OP9:OP9&#8208;Dll1 1:1 layers for amplification (T0 reference samples). Secondary recipients were sacrificed after development of leukemia, and T1 samples were generated from BMs, spleens, and thymi, which confirmed BM infiltration &gt;&#160;20%). T1 and T0 samples were deep sequenced, and changes in individual shRNAs were calculated.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>32421</offset>
      <text>Scatterplot depicting the averaged quantitative changes (log10) of each shRNA within the library in the T1 spleen and BM samples in reference to T0. The changes in both organs were concordant (R2&#160;=&#160;0.72). T1 samples from 11 mice were compared to 3 T0 reference samples. Blue dots represent shRNAs with a significant depletion by &#8805;&#160;10&#8208;fold.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>32768</offset>
      <text>Top five genes with &#8805;&#160;10&#8208;fold shRNA depletion in BM, spleen, and thymus in comparison with the reference.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>32879</offset>
      <text>Percent cell growth of five different DN2&#8208;derived leukemic cell lines transduced with two different shRNA constructs targeting Jak2. The cells were sorted for the GFP or YFP reporter and normalized to the control shRNA targeting the lacZ gene (lacZ). Four of five DN2&#8208;derived leukemias show reduced growth with both shRNAs after the second round of sorting within eight days in culture. The lacZ control was set to 100%.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>33304</offset>
      <text>Proliferation curves of 3 Myc/Bcl2+ DN2&#8208; and 3 GMP&#8208;derived leukemia lines during treatment with 0.5&#160;&#956;M ruxolitinib. 1.5&#160;&#215;&#160;105 cells were seeded in culture and counted at the indicated time points. Results are shown as fold growth relative to the starting cell number which was set to 1. *P&#160;&#8804;&#160;0.05, **P&#160;&#8804;&#160;0.01, Student's t&#8208;test. Error bars define standard deviation (SD), number of replicates n&#160;=&#160;3.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>33724</offset>
      <text>Western blot indicating active Jak/Stat signaling in DN2&#8208;derived leukemia with Stat3 as well as pStat3 protein expression that diminishes after treatment with the Jak&#8208;inhibitor ruxolitinib.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>33918</offset>
      <text>GSEA indicating significant enrichment of genes of the JAK/STAT signaling pathway of the KEGG pathway database in the DN2&#8208;like M2 AML samples as compared to the residual M2 AML samples using the Verhaak AML dataset (Verhaak et&#160;al, 2009). </text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>34160</offset>
      <text>An in&#160;vivo shRNA screen reveals sensitivity to Jak2/Stat3&#8208;pathway inhibition</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>34240</offset>
      <text>We next sought to explore other therapeutic options to target DN2&#8208;leukemia. To this end, we conducted an in&#160;vivo genetic loss&#8208;of&#8208;function screen using an in&#8208;house generated retroviral library expressing shRNAs against 142 genes selected for their general roles in leukemogenesis and/or HSC function (Dataset EV6). We isolated primary Myc/Bcl2+ DN2&#8208;leukemic cells from diseased mice and transduced them with the pooled shRNAs (Fig&#160;7B), after which the transduced cells were sorted and either processed as reference samples or intravenously injected into sublethally irradiated secondary hosts. Upon harvesting the BM, spleen and thymi of the diseased hosts, we determined the relative frequencies of each integrated shRNA (compared to reference samples) by deep sequencing. The shRNA frequency changes&#160;correlated in the three analyzed organs (Fig&#160;7C and Appendix&#160;Fig&#160;S8A). Depletion of a particular shRNA during the disease course indicated a candidate target gene promoting Myc/Bcl2+ DN2&#8208;leukemogenesis. Strikingly, among the five top candidate genes, two were different components of the Jak/Stat pathway, Jak2 and Stat3 (Fig&#160;7D).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>35391</offset>
      <text>To corroborate a functional role of Jak/Stat signaling, we retrovirally transduced five Myc/Bcl2+ cell lines derived from independent primary DN2&#8208;leukemic mice with two different shRNAs targeting Jak2. After demonstrating Jak2 knockdown (Appendix&#160;Fig&#160;S8B), we performed proliferation assays in culture (Fig&#160;7E). Indeed, with the exception of one outlier, Jak2 knockdown reproducibly impaired proliferation of the DN2&#8208;leukemic lines.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>35831</offset>
      <text>Jak2 (and Jak1) can be selectively inhibited by ruxolitinib, which is approved for the treatment of myelofibrosis (Treanor et&#160;al, 2014). To determine whether ruxolitinib would have an anti&#8208;proliferative effect, we cultured murine Myc/Bcl2+ DN2&#8208;leukemic lines with the drug and measured proliferation. To test specificity, we also treated cell lines derived from sick Myc/Bcl2+ GMP&#8208; and LSK&#8208;transplanted mice. All of the DN2&#8208; but none of the GMP&#8208; or LSK&#8208;derived lines showed a significant retardation in cell growth (Fig&#160;7F and Appendix&#160;Fig&#160;S8C). We confirmed activated STAT3 and its inhibition by ruxolitinib in the DN2&#8208;leukemic lines (Fig&#160;7G). Finally, significant enrichment of JAK/STAT signaling signature genes suggested that this pathway is also activated in human DN2&#8208;like M2 AML cells (Fig&#160;7H). Collectively, these results propose Jak2/Stat3 signaling as a potentially druggable target in DN2&#8208;leukemogenesis.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>36773</offset>
      <text>Discussion</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>36784</offset>
      <text>In the present study, we demonstrated that oncogene&#8208;transformed murine DN2 T&#8208;cell progenitors harbor malignant multi&#8208;lineage capacity and a high intrinsic potential to transdifferentiate into myeloid and biphenotypic leukemia. Focusing particularly on the myeloid disease, we showed that DN2&#8208;derived leukemia is characterized by several unique features: It has (i) transcriptional similarity with DCs, (ii) functional thymic origin memory, (iii) persisting myeloid/T&#8208;lymphoid plasticity, (iv) resistance to standard chemotherapy, and (v) dependency on Jak2/Stat3 signaling. Importantly, we identified a possibly correlating human AML cohort (comprising ~5% of all cases) of potential thymic origin and pathogenesis similar to the murine disease. Congruently, the disease of the human cohort may represent a new subgroup of thymus&#8208;derived AML. Moreover, our results propose a general model in which not&#8208;yet&#8208;fully stabilized competing differentiation states of developing progenitors shape plastic lineage identities in cancer.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>37826</offset>
      <text>Leukemic lineage outcomes of T&#8208;cell progenitors have not yet been systematically investigated. To dissect possible lineage fate options of transformed DN2 cells, we delivered ectopic expression of Myc together with Bcl2 and compared these cells with equally treated LSK and GMP cells. In humans, MYC expression is increased (e.g., through activating NOTCH1 mutations) in more than 50% of T&#8208;ALLs (Palomero et&#160;al, 2006; Weng et&#160;al, 2006) and more than 40% of AMLs (Larramendy et&#160;al, 2002; Court et&#160;al, 2004). Overall, this highlights that MYC is among the most frequently upregulated proto&#8208;oncogenes in human acute leukemias and thus represents a useful model in our study. Although there are already published experimental examples of lymphoid/myeloid infidelity in leukemia, it has remained unclear if the transforming oncogenic events inadvertently activate this plasticity, thus overshadowing the possibility that plasticity is an endogenous characteristic of the transformed cells. MYC has been suggested to function as a general amplifier of gene expression rather than activating specific target gene sets (Lin et&#160;al, 2012; Nie et&#160;al, 2012). Although this view has recently been challenged (Sabo et&#160;al, 2014; Koh et&#160;al, 2015), our single cell&#8208;based experiments suggest at the functional level that ectopic Myc expression &#8220;freezes&#8221; endogenous lineage fate options because the lineage outcomes of Myc&#8208;transformed progenitors were similar to those of their healthy counterparts (Bell &amp; Bhandoola, 2008; Wada et&#160;al, 2008; Richie Ehrlich et&#160;al, 2011). Thus, ectopic Myc expression appeared instrumental to dissect endogenous lineage options of transformed hematopoietic cells. Moreover, transformation of DN2 cells by MLL&#8208;AF9 also produced multi&#8208;lineage leukemias, providing further evidence for an intrinsic myeloid/T&#8208;lymphoid potential. Finally, this conclusion also agrees with the myeloid&#8208;based model of hematopoiesis, which explains the retained myeloid potential in other lineages (Kawamoto et&#160;al, 2010).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>39870</offset>
      <text>We focused our study primarily on the myeloid fraction of Myc/Bcl2+ DN2&#8208;derived leukemia and found several unique properties, one of which was expression of DC genes. Previous reports have shown DC potential of healthy thymic progenitors (Li et&#160;al, 2009; Moore et&#160;al, 2012), thus explaining our observation that DC&#8208;like blasts arise from transformed DN2 cells. Another unique feature of DN2&#8208;derived myeloid blasts was that they expressed a gene set shared by normal DN2 T&#8208;cell progenitors. This set likely represents an inherited transcriptional ancestor memory and includes genes encoding important T&#8208;cell transcription factors such as Bcl11b and Gata3, which, as our knockdown data show, are required for DN2&#8208;leukemia growth. Congruently, genes of the T&#8208;cell origin memory are of functional importance.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>40691</offset>
      <text>Another important question we addressed in this study was if mouse model DN2&#8208;leukemia has a human disease counterpart. We approached this by comparing orthologous gene expression. The most obvious correlating human disease seemed to be the recently described ETP&#8208;ALL, which is believed to arise from the earliest thymic precursors and expresses lymphoid together with myeloid and stem cell antigens on the diseased cells (Coustan&#8208;Smith et&#160;al, 2009; Zhang et&#160;al, 2012; Treanor et&#160;al, 2014). However, GSEA with two independently published ETP&#8208;ALL gene signatures clearly showed that DN2&#8208;leukemia is a different disease. Supporting this, ETP&#8208;ALL has shown stronger correlation in gene expression with human HSCs and GMPs than with ETPs (Zhang et&#160;al, 2012). Moreover, ETP&#8208;ALL lacks GATA3 and BCL11B expression (Zhang et&#160;al, 2012), while DN2&#8208;leukemia requires both factors. In contrast with ETP&#8208;ALL, comparing the DN2&#8208;leukemia gene signature with published AML transcriptome data (Verhaak et&#160;al, 2009; Haferlach et&#160;al, 2010) allowed us to identify a novel patient cluster of immature AMLs that significantly resembles mouse DN2&#8208;leukemia. Importantly, these patients expressed significantly more TCR alpha mRNA than the other AML patients. Furthermore, our first preliminary analysis of two DN2&#8208;like AML patients from which genomic DNA was available, suggested TCR rearrangement in at least one of them (data not shown), supporting the view that a transformed T cell served as the ancestor. The DN2&#8208;like human AMLs harbored mutations in DNMT3a, FLT3, IDH1, IDH2, and NPM1, all of which are frequent in AML (Falini et&#160;al, 2011; Patel et&#160;al, 2011; How et&#160;al, 2013; Mayle et&#160;al, 2015). Interestingly, with the exception of NPM1, all of these mutations have also been found in T&#8208;ALL (Van Vlierberghe et&#160;al, 2005, 2013; Grossmann et&#160;al, 2013; Neumann et&#160;al, 2013), and their occurrence in both lineages has been explained by the assumption that they were acquired in a stem cell (Matutes et&#160;al, 1997; Dorantes&#8208;Acosta &amp; Pelayo, 2012). Supporting this notion, we detected significant plasticity in leukemias derived from LSK cells. In this context, it was interesting that in addition to the polyclonal leukemic T&#8208;lymphoid fractions that developed in Myc/Bcl2+ LSK&#8208;transplanted mice, some of the animals also had monoclonal biphenotypic fractions (Appendix&#160;Fig&#160;S9). This finding suggests that individual T&#8208;lymphoid leukemia clones had the plasticity to switch their phenotype in&#160;vivo. Moreover, because we found that DN2 cells had leukemic multi&#8208;lineage potential, an important conclusion from our study could be that the same mutations in T&#8208;ALL and AML may also originate from a transformed T&#8208;cell progenitor instead of a stem cell. In line, the view of a T&#8208;cell ancestor for certain AMLs is supported by studies that have observed frequent TCR rearrangement in MLL&#8208;translocated adult AML and the hypogranular variant subtype of acute promyelocytic leukemia (APL) (Dupret et&#160;al, 2005; Chapiro et&#160;al, 2006).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>43752</offset>
      <text>Our data suggest that biphenotypic leukemia&#8212;now termed mixed&#8208;lineage acute leukemia (MPAL) by the WHO (Borowitz et&#160;al, 2008)&#8212;may develop from T&#8208;cell progenitors as well. Many of these cases carry rearrangement or deletions of the TCR or immunoglobulin heavy chain genes (Buccheri et&#160;al, 1993), underlining the idea that a transformed lymphoid progenitor with residual myeloid potential could be their origin. Importantly, patients with biphenotypic leukemia have a worse clinical outcome than matched AML or ALL patients, and there is no set therapy for this disease (reviewed in Weinberg &amp; Arber, 2010). Hence, pathogenic mechanisms leading to biphenotypic leukemia are of high clinical interest.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>44460</offset>
      <text>A key feature of DN2&#8208;leukemia in mice was its myeloid/T&#8208;lymphoid plasticity, which we linked to dynamic PU.1 expression. PU.1 is an important transcription factor for myeloid differentiation, and forcing its expression can lead to reprogramming of normal lymphoid into myeloid cells (Laiosa et&#160;al, 2006a,b). During normal T&#8208;cell development, PU.1 expression is switched off between the DN2 and DN3 stages, representing the point in time when myeloid potential is lost (Rothenberg et&#160;al, 2008). From the results presented herein, it appears that the DN2&#8208;derived leukemia blasts inherited a unique epigenetic flexibility to dynamically control PU.1 expression from their healthy ancestors. Importantly, because our single&#8208;cell assays revealed that not all DN2&#8208;derived blasts had the same potential to switch phenotype, it is likely that this epigenetic flexibility is confined to special plastic cells within the leukemia population. On the other hand, lineage plasticity in leukemia can also result from particular properties of the transforming oncogene. For example, the CALM&#8208;AF10 t(10:11) fusion product can drive transdifferentiation of&#160;B&#8208;cell progenitors into leukemia with a myeloid phenotype (Deshpande et&#160;al, 2006). Thus, lineage infidelity in leukemia likely involves both intrinsic programs inherited from the healthy ancestor cells and epigenetic properties as a result of the transforming events.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>45888</offset>
      <text>Why might lineage infidelity be advantageous for a leukemia cell? The answer might relate to the fact that lineage switching can be observed after treatment&#8208;associated leukemia relapse; this switching includes the conversion of myeloid to lymphoid leukemia or vice versa (Stass et&#160;al, 1984; Gagnon et&#160;al, 1989; Liso et&#160;al, 1998). Indeed, lineage plasticity in human leukemia is associated with particularly poor survival (Matutes et&#160;al, 1997; Killick et&#160;al, 1999; Golemovic et&#160;al, 2006). In this context, we also investigated a drug response scenario and found that treating DN2&#8208;leukemic cells with daunorubicin or doxorubicin&#8212;both frequently used drugs for human AML therapy (Estey &amp; Dohner, 2006; Estey, 2009)&#8212;negligibly affected the&#160;survival of Myc/Bcl2+ DN2&#8208;leukemic cells. Therefore, we were eager to uncover pathways in DN2&#8208;leukemia that might serve as druggable targets. Because shRNA libraries are instrumental for identifying such targets (Miller et&#160;al, 2013; Sroczynska et&#160;al, 2014), we developed a retroviral shRNA library and conduced an in&#160;vivo genetic loss&#8208;of&#8208;function screen. Importantly, Jak2 and Stat3 arose as top candidates. JAK2 mutations are frequent in polycythemia vera (Scott et&#160;al, 2007), thrombocythemia (Campbell et&#160;al, 2005), and myelofibrosis (Campbell et&#160;al, 2006), and specific JAK2 inhibitors such as ruxolitinib are now in clinical use (Eghtedar et&#160;al, 2012; Harrison et&#160;al, 2012). Indeed, ruxolitinib treatment led to impaired growth of DN2&#8208; but neither GMP&#8208; nor LSK&#8208;derived leukemia, indicating that JAK2 inhibition may be clinically beneficial. This view is supported by our finding that the human DN2&#8208;like AML samples also had enriched expression of the KEGG database JAK/STAT pathway signature, indicative of activated JAK/STAT signaling.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>47704</offset>
      <text>Taken together, this study presents evidence that T&#8208;cell progenitors may represent the cellular origin of a unique type of lineage&#8208;unstable leukemia. More generally, our results propose that in cancer, the cells' associated plasticity, growth, and therapy responses can be the result of genetic programs inherited from healthy ancestor cells. Thus, determining the ancestry of human cancers may aid the development of better treatment protocols.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>48154</offset>
      <text>Materials and Methods</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>48176</offset>
      <text>Mice and cell lines</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>48196</offset>
      <text>Thymus and BM were extracted from 6&#8208; to 12&#8208;week&#8208;old WT BL6 (C57BL/6) donor mice, purchased from Charles River Laboratories. Myc/Bcl2+ LSKs, GMPs, or DN2 cells were intravenously or intrathymically injected into B6.SJL (B6.SJL&#8208;Ptprca/BoyAiTac) congenic recipient mice. BL6 mice express CD45.2 (Ly5.2; Ptprc; protein tyrosine phosphatase, receptor type, C) and B6.SJL CD45.1 (Ly5.1; Ptprc; protein tyrosine phosphatase, receptor type, C), allowing for distinction of leukemic donor and healthy recipient cells. All mouse experiments were approved by the local authorities according to the German Federal Animal Protection Act.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>48829</offset>
      <text>Transplantation experiments</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>48857</offset>
      <text>For cell transfer, we used 4&#8208; to 8&#8208;week&#8208;old recipient mice that received 4.5&#8211;6&#160;Gy total body irradiation with the 18&#160;MeV photon&#160;beam of a linear electron accelerator using a dose rate of 6.79&#160;Gy/min or the Faxitron CP160 X&#8208;ray irradiation system with 0.55 Cu filter and a dose of 0.603&#160;Gy/min. 2&#160;&#215;&#160;104&#8211;1&#160;&#215;&#160;106 malignant cells were intravenously injected. Leukocytosis with blast counts &gt;&#160;10% in peripheral blood derived from donor cells indicated acute leukemia (20% bone marrow infiltration). If recipient animals showed physical signs of full&#8208;blown leukemia (hind limb paralysis, loss of body weight, palpable spleen, or submandibular lymph nodes), they were euthanized. Intrathymic injections were performed as previously described (Goldschneider et&#160;al, 1986). Recipient mice were narcotized with a mixture of ketamine&#8211;xylazine, fixated with the ventral side pointing upwards the sterilized thorax area, and opened with a medial longitudinal skin section to expose the thymus. 3&#160;&#215;&#160;104 donor cells were injected with a 27G canula into the two lobes of the thymus and the incision closed with wound clips.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>49996</offset>
      <text>Histology</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>50006</offset>
      <text>Maximally 1&#160;&#215;&#160;104 of cells were cytospun (Tharmac) at 33.5&#160;g for 10&#160;min onto object slides. Air&#8208;dried object slides were fixed in methanol for 10&#160;min and incubated 10&#160;min in May&#8208;Gruenwald staining solution (Sigma&#8208;Aldrich). Slides were washed with water and stained with Giemsa staining solution (Sigma&#8208;Aldrich) for 40&#160;min. After the final washing step with water, slides were air&#8208;dried and closed with a drop of Roti&#174;&#8208;Histokitt II and cover slips. For histology, parts of the spleen, sternum, or liver were transferred into a Histofix solution (Roth) and cross sections were prepared as described previously (Erny et&#160;al, 2015). May&#8208;Gruenwald Giemsa (MGG) and Myeloperoxidase (Ab&#8208;1, RB 373&#8208;A0 Thermo Scientific, 1:200) staining was conducted, and the slides were photographed with an Axioplan2 microscope/camera system (Zeiss).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>50861</offset>
      <text>Flow cytometry and cell sorting</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>50893</offset>
      <text>Twenty 4&#8208; to 5&#8208;week&#8208;old donor mice were sacrificed per experiment to obtain approximately 5&#160;&#215;&#160;104 DN2 cells from thymi and 6&#160;&#215;&#160;104 LSK and 1&#160;&#215;&#160;105 GMP from BM washout. Single&#8208;cell suspensions from thymi and BM were stained with the following antibodies conjugated with V450, PE, APC, or FITC: CD3 (500A2), CD4 (RM4&#8208;5), CD8a (53&#8208;6.7), CD19 (1D3), Gr1 (RB6&#8208;8C5), CD11b (M1/70), CD45R/B220 (RA3&#8208;6B2), CD25 (PC61), Fc&#947;RII/III (2.4G2), CD34 (RAM34), Sca&#8208;1 (D7), and c&#8208;Kit (2B8). Thymic and BM suspensions were incubated with CD117 (c&#8208;Kit) mouse microbeads (Miltenyi) according to the instructions of the supplier and enriched for c&#8208;Kit via magnetic cell separation in MACS LS columns (Miltenyi). Cell sorting was performed with a high&#8208;speed multi&#8208;color cell sorter (Aria II or III). Thymic precursors were defined via surface markers as described previously (Wada et&#160;al, 2008). All cells were sorted by exclusion of 7&#8208;AAD+ dead cells as well as doublets. After sorting, an aliquot of the sorted fractions was used for re&#8208;analysis and confirmation of at least 95% sort purity.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>52007</offset>
      <text>Primary leukemias were analyzed by FACS with antibodies against CD3 (145&#8208;2C11), CD4 (RM4&#8208;5), CD8 (53&#8208;6.7), CD11b (M1/70.15), Gr1 (RB6&#8208;8C5), CD45.1 (A20) and CD45.2 (104), TCR beta (H57&#8208;597), or TCR gamma/delta (GL3) conjugated with PE, APC, Pacific and Alexa Fluor 700. Intracellular CD3 staining was performed by Cell Fixation/Permeabilization Kits (BD).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>52373</offset>
      <text>Plasmids</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>52382</offset>
      <text>MSCV&#8208;c&#8208;Myc&#8208;IRES&#8208;Bcl2 was described in Luo et&#160;al (2005). The shRNA library was subcloned into the PINCO&#8208;RFB&#8208;GFP&#8208;IRES&#8208;RE9 (Grignani et&#160;al, 1998) following the BLOCK&#8208;iT&#8482; Pol II miR RNAi Expression Vector Kit (Invitrogen) together with the Gateway&#174; technology (Invitrogen). shRNAs against Bcl11b, Gata3, and luciferase were subcloned into the pRSI9&#8208;U6&#8208;(sh)&#8208;UbiC&#8208;TagRFP&#8208;2A&#8208;Puro (Addgene) following the Cellecta protocol. All shRNA sequences are available on request. The plasmids pLP1, pLP2 and VSVG, and pcDNA&#8482; 6.2&#8208;GW/&#177;&#160;EmGFP&#8208;miR&#8208;lacZ were from Invitrogen. MSCV&#8208;IRES&#8208;GFP&#8208;IRES&#8208;PU.1 was described in Rosenbauer et&#160;al (2004) and MSCV&#8208;IRES&#8208;GFP in Huntly et&#160;al (2004).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>53101</offset>
      <text>In vitro colony forming assays and single&#8208;cell sorts</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>53156</offset>
      <text>Semi&#8208;solid culture of transformed precursors in methylcellulose was used to generate immobilized colonies; 24&#8208;h postinfection, ~1,000 Myc/Bcl2&#8208;transduced cells were plated in methylcellulose (M3234, Stem Cell Technologies) supplemented with 10&#160;ng/ml IL&#8208;2, IL&#8208;3, IL&#8208;6, IL&#8208;7, SCF, GM&#8208;CSF, FLT3, and 20&#160;&#956;g/ml gentamicin; 500&#160;ng/ml Fungizole; and 20&#160;&#956;g/ml ciprofloxacin. Methylcellulose suspensions were plated onto 35&#8208;mm cell culture dishes for 5&#8211;7&#160;days before leukemic colonies were picked and separately expanded in a 96&#8208;well plate with fresh methylcellulose. Clones were expanded for extraction of genomic DNA.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>53796</offset>
      <text>Western blot analysis</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>53818</offset>
      <text>Protein samples were prepared as described in Rosenbauer et&#160;al (2006). Proteins were detected with the antibodies anti&#8208;Ctip2/Bcl11b (25B6) (Abcam), anti&#8208;GATA&#8208;3 (510&#8208;20) (Abcam), anti&#8208;&#946;&#8208;actin (AC&#8208;15 or A2066) (Sigma&#8208;Aldrich), anti&#8208;&#945;&#8208;tubulin (B&#8208;5&#8208;1&#8208;2) (Santa Cruz), anti&#8208;VCP (5) (Abcam), anti&#8208;PU.1 (T&#8208;21X) (Santa Cruz), anti&#8208;pStat3 (Tyr705) (D3A7) (Cell Signaling Technology), and anti&#8208;Stat3 (124H6) (Cell Signaling Technology). For the detection of horseradish peroxidase coupled secondary antibodies, the ECL kit (Invitrogen) was used.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>54393</offset>
      <text>Gene expression profiling</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>54419</offset>
      <text>The Affymetrix GeneChip&#174; (Mus musculus) MG 430 PM was applied to investigate the expression of approximately 45,000 features in flow&#8208;sorted LSK&#8208;, GMP&#8208;, and DN2&#8208;derived myeloid leukemia cells. Sample processing and microarray hybridization were carried out at the Center of Excellence for Fluorescent Bioanalytics (KFB, University of Regensburg, Germany). The raw gene expression data were imported into R (R Core Team, 2015) and RMA normalized with the R package &#8220;affy&#8221; (Gautier et&#160;al, 2004). Murine gene signature generation, gene set enrichment analysis, and identification of human AML samples correlating to mouse DN2&#8208;leukemia are described in detail in the Appendix Supplementary Methods.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>55129</offset>
      <text>Statistical analysis</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>55150</offset>
      <text>No statistical methods were used to predetermine sample sizes, and exact group numbers were determined by animal availability. However, we did ensure that our sample sizes were similar to those generally employed in the field. To obtain unbiased data, experimental mice were not randomized or blinded but processed by scientists together with technicians and cell quantifications were performed by two scientists independently and separately. Microarray analysis was blinded, and sample preparation, processing, and analysis were performed by different scientists.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>55715</offset>
      <text>Two&#8208;tailed Student's t&#8208;test was carried out to determine the statistical significance of experimental results for normally distributed values. *P&#160;&#8804;&#160;0.05 and **P&#160;&#8804;&#160;0.01. Alternatively, Wilcoxon rank&#8208;sum tests were used to determine statistical significance. **P&#160;&#8804;&#160;0.01.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>56002</offset>
      <text>Accession codes</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>56018</offset>
      <text>GEO: array data, GSE80739.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>56045</offset>
      <text>Author contributions</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>56066</offset>
      <text>PR, MC, JF, SG, VG, DL, and AW conducted experiments. CW, MZ, MLG, NM, and MG analyzed data; KA and SL generated the shRNA library; TH and RD provided patient data; MP conducted pathological analyses; MAA&#8208;N, GL, MD, and CM&#8208;T provided experimental support and supervised parts of this study. PR and FR designed the study and wrote the manuscript. FR supervised the entire project and provided financial support.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>56481</offset>
      <text>Conflict of interest</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>56502</offset>
      <text>The authors declare that they have no conflict of interest.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>56562</offset>
      <text>Supporting information</text>
    </passage>
    <passage>
      <infon key="type">title</infon>
      <offset>56585</offset>
      <text>References</text>
    </passage>
    <passage>
      <infon key="volume">452</infon>
      <infon key="source">Nature</infon>
      <infon key="lpage">767</infon>
      <infon key="pub-id_pmid">18401411</infon>
      <infon key="fpage">764</infon>
      <infon key="year">2008</infon>
      <infon key="type">ref</infon>
      <offset>56596</offset>
      <text>The earliest thymic progenitors for T cells possess myeloid lineage potential</text>
    </passage>
    <passage>
      <infon key="volume">9</infon>
      <infon key="source">Leukemia</infon>
      <infon key="lpage">1786</infon>
      <infon key="pub-id_pmid">7564526</infon>
      <infon key="fpage">1783</infon>
      <infon key="year">1995</infon>
      <infon key="type">ref</infon>
      <offset>56674</offset>
      <text>Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Harris;given-names:NL</infon>
      <infon key="name_3">surname:Jaffe;given-names:ES</infon>
      <infon key="name_0">surname:Swerdlow;given-names:SH</infon>
      <infon key="name_1">surname:Campo;given-names:E</infon>
      <infon key="name_6">surname:Thiele;given-names:J</infon>
      <infon key="name_7">surname:Vardiman;given-names:JW</infon>
      <infon key="name_4">surname:Pileri;given-names:SA</infon>
      <infon key="name_5">surname:Stein;given-names:H</infon>
      <infon key="lpage">155</infon>
      <infon key="source">WHO Classification of Tumours of Heamatopoietic and Lymphoid Tissues</infon>
      <infon key="fpage">150</infon>
      <infon key="year">2008</infon>
      <infon key="type">ref</infon>
      <offset>56815</offset>
      <text></text>
    </passage>
    <passage>
      <infon key="volume">7</infon>
      <infon key="source">Leukemia</infon>
      <infon key="lpage">927</infon>
      <infon key="pub-id_pmid">8501986</infon>
      <infon key="fpage">919</infon>
      <infon key="year">1993</infon>
      <infon key="type">ref</infon>
      <offset>56816</offset>
      <text>Lineage commitment in biphenotypic acute leukemia</text>
    </passage>
    <passage>
      <infon key="volume">366</infon>
      <infon key="source">Lancet</infon>
      <infon key="lpage">1953</infon>
      <infon key="pub-id_pmid">16325696</infon>
      <infon key="fpage">1945</infon>
      <infon key="year">2005</infon>
      <infon key="type">ref</infon>
      <offset>56866</offset>
      <text>Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study</text>
    </passage>
    <passage>
      <infon key="volume">107</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">2100</infon>
      <infon key="pub-id_pmid">16293597</infon>
      <infon key="fpage">2098</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>57011</offset>
      <text>V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis</text>
    </passage>
    <passage>
      <infon key="volume">12</infon>
      <infon key="source">Nat Med</infon>
      <infon key="lpage">213</infon>
      <infon key="pub-id_pmid">16444266</infon>
      <infon key="fpage">207</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>57097</offset>
      <text>Interferon&#8208;producing killer dendritic cells provide a link between innate and adaptive immunity</text>
    </passage>
    <passage>
      <infon key="volume">108</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">3493</infon>
      <infon key="pub-id_pmid">16857994</infon>
      <infon key="fpage">3484</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>57195</offset>
      <text>Expression of T&#8208;lineage&#8208;affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17)</text>
    </passage>
    <passage>
      <infon key="volume">163</infon>
      <infon key="source">J Exp Med</infon>
      <infon key="lpage">424</infon>
      <infon key="pub-id_pmid">3080546</infon>
      <infon key="fpage">414</infon>
      <infon key="year">1986</infon>
      <infon key="type">ref</infon>
      <offset>57351</offset>
      <text>T cell receptor and immunoglobulin gene rearrangements in acute myeloblastic leukemia</text>
    </passage>
    <passage>
      <infon key="volume">28</infon>
      <infon key="source">Leuk Res</infon>
      <infon key="lpage">753</infon>
      <infon key="pub-id_pmid">15158096</infon>
      <infon key="fpage">743</infon>
      <infon key="year">2004</infon>
      <infon key="type">ref</infon>
      <offset>57437</offset>
      <text>DNA microarray screening of differential gene expression in bone marrow samples from AML, non&#8208;AML patients and AML cell lines</text>
    </passage>
    <passage>
      <infon key="volume">10</infon>
      <infon key="source">Lancet Oncol</infon>
      <infon key="lpage">156</infon>
      <infon key="pub-id_pmid">19147408</infon>
      <infon key="fpage">147</infon>
      <infon key="year">2009</infon>
      <infon key="type">ref</infon>
      <offset>57565</offset>
      <text>Early T&#8208;cell precursor leukaemia: a subtype of very high&#8208;risk acute lymphoblastic leukaemia</text>
    </passage>
    <passage>
      <infon key="volume">121</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">71</infon>
      <infon key="pub-id_pmid">23152541</infon>
      <infon key="fpage">64</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>57661</offset>
      <text>Early T&#8208;cell progenitors are the major granulocyte precursors in the adult mouse thymus</text>
    </passage>
    <passage>
      <infon key="volume">10</infon>
      <infon key="source">Cancer Cell</infon>
      <infon key="lpage">374</infon>
      <infon key="pub-id_pmid">17097559</infon>
      <infon key="fpage">363</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>57751</offset>
      <text>Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10&#8208;positive leukemia</text>
    </passage>
    <passage>
      <infon key="volume">115</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">474</infon>
      <infon key="pub-id_pmid">19880497</infon>
      <infon key="fpage">453</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>57892</offset>
      <text>Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet</text>
    </passage>
    <passage>
      <infon key="source">Bone Marrow Res</infon>
      <infon key="volume">2012</infon>
      <infon key="pub-id_pmid">22852088</infon>
      <infon key="fpage">406796</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>58044</offset>
      <text>Lineage switching in acute leukemias: a consequence of stem cell plasticity?</text>
    </passage>
    <passage>
      <infon key="volume">19</infon>
      <infon key="source">Leukemia</infon>
      <infon key="lpage">2338</infon>
      <infon key="pub-id_pmid">16304577</infon>
      <infon key="fpage">2337</infon>
      <infon key="year">2005</infon>
      <infon key="type">ref</infon>
      <offset>58121</offset>
      <text>IgH/TCR rearrangements are common in MLL translocated adult AML and suggest an early T/myeloid or B/myeloid maturation arrest, which correlates with the MLL partner</text>
    </passage>
    <passage>
      <infon key="volume">119</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">4618</infon>
      <infon key="pub-id_pmid">22422826</infon>
      <infon key="fpage">4614</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>58286</offset>
      <text>Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia</text>
    </passage>
    <passage>
      <infon key="volume">18</infon>
      <infon key="source">Nat Neurosci</infon>
      <infon key="lpage">977</infon>
      <infon key="pub-id_pmid">26030851</infon>
      <infon key="fpage">965</infon>
      <infon key="year">2015</infon>
      <infon key="type">ref</infon>
      <offset>58444</offset>
      <text>Host microbiota constantly control maturation and function of microglia in the CNS</text>
    </passage>
    <passage>
      <infon key="volume">368</infon>
      <infon key="source">Lancet</infon>
      <infon key="lpage">1907</infon>
      <infon key="pub-id_pmid">17126723</infon>
      <infon key="fpage">1894</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>58527</offset>
      <text>Acute myeloid leukaemia</text>
    </passage>
    <passage>
      <infon key="volume">94</infon>
      <infon key="source">Haematologica</infon>
      <infon key="lpage">16</infon>
      <infon key="pub-id_pmid">19118375</infon>
      <infon key="fpage">10</infon>
      <infon key="year">2009</infon>
      <infon key="type">ref</infon>
      <offset>58551</offset>
      <text>Treatment of acute myeloid leukemia</text>
    </passage>
    <passage>
      <infon key="volume">25</infon>
      <infon key="source">Blood Rev</infon>
      <infon key="lpage">254</infon>
      <infon key="pub-id_pmid">21724308</infon>
      <infon key="fpage">247</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>58587</offset>
      <text>Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?</text>
    </passage>
    <passage>
      <infon key="volume">74</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">2095</infon>
      <infon key="pub-id_pmid">2553159</infon>
      <infon key="fpage">2088</infon>
      <infon key="year">1989</infon>
      <infon key="type">ref</infon>
      <offset>58678</offset>
      <text>Molecular heterogeneity in acute leukemia lineage switch</text>
    </passage>
    <passage>
      <infon key="volume">20</infon>
      <infon key="source">Bioinformatics</infon>
      <infon key="lpage">315</infon>
      <infon key="pub-id_pmid">14960456</infon>
      <infon key="fpage">307</infon>
      <infon key="year">2004</infon>
      <infon key="type">ref</infon>
      <offset>58735</offset>
      <text>affy&#8211;analysis of Affymetrix GeneChip data at the probe level</text>
    </passage>
    <passage>
      <infon key="volume">148</infon>
      <infon key="source">Cell</infon>
      <infon key="lpage">1098</infon>
      <infon key="pub-id_pmid">22424221</infon>
      <infon key="fpage">1089</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>58798</offset>
      <text>Converting cancer therapies into cures: lessons from infectious diseases</text>
    </passage>
    <passage>
      <infon key="volume">163</infon>
      <infon key="source">J Exp Med</infon>
      <infon key="lpage">17</infon>
      <infon key="pub-id_pmid">3510267</infon>
      <infon key="fpage">1</infon>
      <infon key="year">1986</infon>
      <infon key="type">ref</infon>
      <offset>58871</offset>
      <text>Studies of thymocytopoiesis in rats and mice I Kinetics of appearance of thymocytes using a direct intrathymic adoptive transfer assay for thymocyte precursors</text>
    </passage>
    <passage>
      <infon key="volume">30</infon>
      <infon key="source">Leukemia Res</infon>
      <infon key="lpage">221</infon>
      <infon key="pub-id_pmid">16102826</infon>
      <infon key="fpage">211</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>59031</offset>
      <text>IgH and TCR&#8208;gamma gene rearrangements, cyclin A1 and HOXA9 gene expression in biphenotypic acute leukemias</text>
    </passage>
    <passage>
      <infon key="volume">58</infon>
      <infon key="source">Cancer Res</infon>
      <infon key="lpage">19</infon>
      <infon key="pub-id_pmid">9426049</infon>
      <infon key="fpage">14</infon>
      <infon key="year">1998</infon>
      <infon key="type">ref</infon>
      <offset>59140</offset>
      <text>High&#8208;efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein</text>
    </passage>
    <passage>
      <infon key="volume">52</infon>
      <infon key="source">Genes Chromosom Cancer</infon>
      <infon key="lpage">422</infon>
      <infon key="pub-id_pmid">23341344</infon>
      <infon key="fpage">410</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>59304</offset>
      <text>The molecular profile of adult T&#8208;cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T&#8208;ALL</text>
    </passage>
    <passage>
      <infon key="volume">28</infon>
      <infon key="source">J Clin Oncol</infon>
      <infon key="lpage">2537</infon>
      <infon key="pub-id_pmid">20406941</infon>
      <infon key="fpage">2529</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>59450</offset>
      <text>Clinical utility of microarray&#8208;based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group</text>
    </passage>
    <passage>
      <infon key="volume">366</infon>
      <infon key="source">N Engl J Med</infon>
      <infon key="lpage">798</infon>
      <infon key="pub-id_pmid">22375970</infon>
      <infon key="fpage">787</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>59644</offset>
      <text>JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis</text>
    </passage>
    <passage>
      <infon key="source">Blood Cancer J</infon>
      <infon key="volume">3</infon>
      <infon key="pub-id_pmid">23708641</infon>
      <infon key="fpage">e116</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>59724</offset>
      <text>The prognostic impact of FLT3&#8208;ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate&#8208;risk cytogenetics</text>
    </passage>
    <passage>
      <infon key="volume">6</infon>
      <infon key="source">Cancer Cell</infon>
      <infon key="lpage">596</infon>
      <infon key="pub-id_pmid">15607963</infon>
      <infon key="fpage">587</infon>
      <infon key="year">2004</infon>
      <infon key="type">ref</infon>
      <offset>59865</offset>
      <text>MOZ&#8208;TIF2, but not BCR&#8208;ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors</text>
    </passage>
    <passage>
      <infon key="volume">238</infon>
      <infon key="source">Immunol Rev</infon>
      <infon key="lpage">36</infon>
      <infon key="pub-id_pmid">20969582</infon>
      <infon key="fpage">23</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>59984</offset>
      <text>A map for lineage restriction of progenitors during hematopoiesis: the essence of the myeloid&#8208;based model</text>
    </passage>
    <passage>
      <infon key="volume">84</infon>
      <infon key="source">Haematologica</infon>
      <infon key="lpage">706</infon>
      <infon key="pub-id_pmid">10457405</infon>
      <infon key="fpage">699</infon>
      <infon key="year">1999</infon>
      <infon key="type">ref</infon>
      <offset>60092</offset>
      <text>Outcome of biphenotypic acute leukemia</text>
    </passage>
    <passage>
      <infon key="volume">526</infon>
      <infon key="source">Nature</infon>
      <infon key="lpage">100</infon>
      <infon key="pub-id_pmid">26416755</infon>
      <infon key="fpage">96</infon>
      <infon key="year">2015</infon>
      <infon key="type">ref</infon>
      <offset>60131</offset>
      <text>MYC regulates the core pre&#8208;mRNA splicing machinery as an essential step in lymphomagenesis</text>
    </passage>
    <passage>
      <infon key="volume">24</infon>
      <infon key="source">Annu Rev Immunol</infon>
      <infon key="lpage">738</infon>
      <infon key="pub-id_pmid">16551264</infon>
      <infon key="fpage">705</infon>
      <infon key="year">2006a</infon>
      <infon key="type">ref</infon>
      <offset>60224</offset>
      <text>Determinants of lymphoid&#8208;myeloid lineage diversification</text>
    </passage>
    <passage>
      <infon key="volume">25</infon>
      <infon key="source">Immunity</infon>
      <infon key="lpage">744</infon>
      <infon key="pub-id_pmid">17088084</infon>
      <infon key="fpage">731</infon>
      <infon key="year">2006b</infon>
      <infon key="type">ref</infon>
      <offset>60283</offset>
      <text>Reprogramming of committed T cell progenitors to macrophages and dendritic cells by C/EBP alpha and PU1 transcription factors</text>
    </passage>
    <passage>
      <infon key="volume">87</infon>
      <infon key="source">Haematologica</infon>
      <infon key="lpage">577</infon>
      <infon key="pub-id_pmid">12031912</infon>
      <infon key="fpage">569</infon>
      <infon key="year">2002</infon>
      <infon key="type">ref</infon>
      <offset>60409</offset>
      <text>Overexpression of translocation&#8208;associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia A microarray analysis</text>
    </passage>
    <passage>
      <infon key="volume">206</infon>
      <infon key="source">J Exp Med</infon>
      <infon key="lpage">622</infon>
      <infon key="pub-id_pmid">19273629</infon>
      <infon key="fpage">607</infon>
      <infon key="year">2009</infon>
      <infon key="type">ref</infon>
      <offset>60579</offset>
      <text>Thymus&#8208;homing peripheral dendritic cells constitute two of the three major subsets of dendritic cells in the steady&#8208;state thymus</text>
    </passage>
    <passage>
      <infon key="volume">151</infon>
      <infon key="source">Cell</infon>
      <infon key="lpage">67</infon>
      <infon key="pub-id_pmid">23021215</infon>
      <infon key="fpage">56</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>60712</offset>
      <text>Transcriptional amplification in tumor cells with elevated c&#8208;Myc</text>
    </passage>
    <passage>
      <infon key="volume">83</infon>
      <infon key="source">Haematologica</infon>
      <infon key="lpage">473</infon>
      <infon key="pub-id_pmid">9658734</infon>
      <infon key="fpage">471</infon>
      <infon key="year">1998</infon>
      <infon key="type">ref</infon>
      <offset>60779</offset>
      <text>T&#8208;cell acute lymphoblastic leukemia occurring in a patient with acute promyelocytic leukemia</text>
    </passage>
    <passage>
      <infon key="volume">106</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">2461</infon>
      <infon key="pub-id_pmid">15972450</infon>
      <infon key="fpage">2452</infon>
      <infon key="year">2005</infon>
      <infon key="type">ref</infon>
      <offset>60874</offset>
      <text>c&#8208;Myc rapidly induces acute myeloid leukemia in mice without evidence of&#160;lymphoma&#8208;associated antiapoptotic mutations</text>
    </passage>
    <passage>
      <infon key="volume">106</infon>
      <infon key="source">Proc Natl Acad Sci USA</infon>
      <infon key="lpage">3401</infon>
      <infon key="pub-id_pmid">19218430</infon>
      <infon key="fpage">3396</infon>
      <infon key="year">2009</infon>
      <infon key="type">ref</infon>
      <offset>60996</offset>
      <text>Dysregulated gene expression networks in human acute myelogenous leukemia stem cells</text>
    </passage>
    <passage>
      <infon key="volume">82</infon>
      <infon key="source">Haematologica</infon>
      <infon key="lpage">66</infon>
      <infon key="pub-id_pmid">9107085</infon>
      <infon key="fpage">64</infon>
      <infon key="year">1997</infon>
      <infon key="type">ref</infon>
      <offset>61081</offset>
      <text>Definition of acute biphenotypic leukemia</text>
    </passage>
    <passage>
      <infon key="volume">125</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">638</infon>
      <infon key="pub-id_pmid">25416277</infon>
      <infon key="fpage">629</infon>
      <infon key="year">2015</infon>
      <infon key="type">ref</infon>
      <offset>61123</offset>
      <text>Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation</text>
    </passage>
    <passage>
      <infon key="volume">24</infon>
      <infon key="source">Cancer Cell</infon>
      <infon key="lpage">58</infon>
      <infon key="pub-id_pmid">23770013</infon>
      <infon key="fpage">45</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>61207</offset>
      <text>In Vivo RNAi screening identifies a leukemia&#8208;specific dependence on integrin beta 3 signaling</text>
    </passage>
    <passage>
      <infon key="volume">139</infon>
      <infon key="source">Development</infon>
      <infon key="lpage">384</infon>
      <infon key="pub-id_pmid">22186727</infon>
      <infon key="fpage">373</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>61303</offset>
      <text>Transcriptional priming of intrathymic precursors for dendritic cell development</text>
    </passage>
    <passage>
      <infon key="source">Blood Cancer J</infon>
      <infon key="volume">2</infon>
      <infon key="pub-id_pmid">22829239</infon>
      <infon key="fpage">e55</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>61384</offset>
      <text>Clinical and molecular characterization of early T&#8208;cell precursor leukemia: a high&#8208;risk subgroup in adult T&#8208;ALL with a high frequency of FLT3 mutations</text>
    </passage>
    <passage>
      <infon key="source">PLoS One</infon>
      <infon key="volume">8</infon>
      <infon key="pub-id_pmid">23359050</infon>
      <infon key="fpage">e53190</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>61542</offset>
      <text>FLT3 mutations in early T&#8208;cell precursor all characterize a stem cell like leukemia and Imply the clinical use of tyrosine kinase inhibitors</text>
    </passage>
    <passage>
      <infon key="volume">151</infon>
      <infon key="source">Cell</infon>
      <infon key="lpage">79</infon>
      <infon key="pub-id_pmid">23021216</infon>
      <infon key="fpage">68</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>61685</offset>
      <text>c&#8208;Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells</text>
    </passage>
    <passage>
      <infon key="volume">103</infon>
      <infon key="source">Proc Natl Acad Sci USA</infon>
      <infon key="lpage">18266</infon>
      <infon key="pub-id_pmid">17114293</infon>
      <infon key="fpage">18261</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>61777</offset>
      <text>NOTCH1 directly regulates c&#8208;MYC and activates a feed&#8208;forward&#8208;loop transcriptional network promoting leukemic cell growth</text>
    </passage>
    <passage>
      <infon key="volume">135</infon>
      <infon key="source">Am J Clin Pathol</infon>
      <infon key="lpage">45</infon>
      <infon key="pub-id_pmid">21173122</infon>
      <infon key="fpage">35</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>61904</offset>
      <text>Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features</text>
    </passage>
    <passage>
      <infon key="source">A language and environment for statistical computing</infon>
      <infon key="type">ref</infon>
      <infon key="year">2015</infon>
      <offset>61996</offset>
      <text></text>
    </passage>
    <passage>
      <infon key="volume">117</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">2624</infon>
      <infon key="pub-id_pmid">21163922</infon>
      <infon key="fpage">2618</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>61997</offset>
      <text>In vitro assays misrepresent in&#160;vivo lineage potentials of murine lymphoid progenitors</text>
    </passage>
    <passage>
      <infon key="volume">117</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">7120</infon>
      <infon key="pub-id_pmid">21562049</infon>
      <infon key="fpage">7112</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>62085</offset>
      <text>Identification of T&#8208;lymphocytic leukemia&#8208;initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease</text>
    </passage>
    <passage>
      <infon key="volume">36</infon>
      <infon key="source">Nat Genet</infon>
      <infon key="lpage">630</infon>
      <infon key="pub-id_pmid">15146183</infon>
      <infon key="fpage">624</infon>
      <infon key="year">2004</infon>
      <infon key="type">ref</infon>
      <offset>62227</offset>
      <text>Acute myeloid leukemia induced by graded reduction of a lineage&#8208;specific transcription factor, PU1</text>
    </passage>
    <passage>
      <infon key="volume">38</infon>
      <infon key="source">Nat Genet</infon>
      <infon key="lpage">37</infon>
      <infon key="pub-id_pmid">16311598</infon>
      <infon key="fpage">27</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>62328</offset>
      <text>Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU1</text>
    </passage>
    <passage>
      <infon key="volume">7</infon>
      <infon key="source">Nat Rev Immunol</infon>
      <infon key="lpage">117</infon>
      <infon key="pub-id_pmid">17259967</infon>
      <infon key="fpage">105</infon>
      <infon key="year">2007</infon>
      <infon key="type">ref</infon>
      <offset>62436</offset>
      <text>Transcription factors in myeloid development: balancing differentiation with transformation</text>
    </passage>
    <passage>
      <infon key="volume">8</infon>
      <infon key="source">Nat Rev Immunol</infon>
      <infon key="lpage">21</infon>
      <infon key="pub-id_pmid">18097446</infon>
      <infon key="fpage">9</infon>
      <infon key="year">2008</infon>
      <infon key="type">ref</infon>
      <offset>62528</offset>
      <text>Launching the T&#8208;cell&#8208;lineage developmental programme</text>
    </passage>
    <passage>
      <infon key="volume">24</infon>
      <infon key="source">Curr Opin Immunol</infon>
      <infon key="lpage">138</infon>
      <infon key="pub-id_pmid">22264928</infon>
      <infon key="fpage">132</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>62585</offset>
      <text>Transcriptional drivers of the T&#8208;cell lineage program</text>
    </passage>
    <passage>
      <infon key="volume">511</infon>
      <infon key="source">Nature</infon>
      <infon key="lpage">492</infon>
      <infon key="pub-id_pmid">25043028</infon>
      <infon key="fpage">488</infon>
      <infon key="year">2014</infon>
      <infon key="type">ref</infon>
      <offset>62641</offset>
      <text>Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis</text>
    </passage>
    <passage>
      <infon key="volume">6</infon>
      <infon key="source">Nat Immunol</infon>
      <infon key="lpage">670</infon>
      <infon key="pub-id_pmid">15951813</infon>
      <infon key="fpage">663</infon>
      <infon key="year">2005</infon>
      <infon key="type">ref</infon>
      <offset>62732</offset>
      <text>Notch signaling controls the generation and differentiation of early T lineage progenitors</text>
    </passage>
    <passage>
      <infon key="volume">32</infon>
      <infon key="source">Immunity</infon>
      <infon key="lpage">436</infon>
      <infon key="pub-id_pmid">20303297</infon>
      <infon key="fpage">426</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>62823</offset>
      <text>Fate mapping reveals separate origins of T cells and myeloid lineages in the thymus</text>
    </passage>
    <passage>
      <infon key="volume">3</infon>
      <infon key="source">Cell Rep</infon>
      <infon key="lpage">1628</infon>
      <infon key="pub-id_pmid">23623495</infon>
      <infon key="fpage">1617</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>62907</offset>
      <text>PU1 level&#8208;directed chromatin structure remodeling at the Irf8 gene drives dendritic cell commitment</text>
    </passage>
    <passage>
      <infon key="volume">356</infon>
      <infon key="source">N Engl J Med</infon>
      <infon key="lpage">468</infon>
      <infon key="pub-id_pmid">17267906</infon>
      <infon key="fpage">459</infon>
      <infon key="year">2007</infon>
      <infon key="type">ref</infon>
      <offset>63009</offset>
      <text>JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis</text>
    </passage>
    <passage>
      <infon key="volume">123</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">1882</infon>
      <infon key="pub-id_pmid">24501218</infon>
      <infon key="fpage">1870</infon>
      <infon key="year">2014</infon>
      <infon key="type">ref</infon>
      <offset>63083</offset>
      <text>shRNA screening identifies JMJD1C as being required for leukemia maintenance</text>
    </passage>
    <passage>
      <infon key="volume">64</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">706</infon>
      <infon key="pub-id_pmid">6590097</infon>
      <infon key="fpage">701</infon>
      <infon key="year">1984</infon>
      <infon key="type">ref</infon>
      <offset>63160</offset>
      <text>Lineage switch in acute leukemia</text>
    </passage>
    <passage>
      <infon key="volume">63</infon>
      <infon key="source">Cancer Res</infon>
      <infon key="lpage">7041</infon>
      <infon key="pub-id_pmid">14612491</infon>
      <infon key="fpage">7038</infon>
      <infon key="year">2003</infon>
      <infon key="type">ref</infon>
      <offset>63193</offset>
      <text>Identification of COX17 as a therapeutic target for non&#8208;small cell lung cancer</text>
    </passage>
    <passage>
      <infon key="volume">211</infon>
      <infon key="source">J Exp Med</infon>
      <infon key="lpage">713</infon>
      <infon key="pub-id_pmid">24687960</infon>
      <infon key="fpage">701</infon>
      <infon key="year">2014</infon>
      <infon key="type">ref</infon>
      <offset>63274</offset>
      <text>Interleukin&#8208;7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential</text>
    </passage>
    <passage>
      <infon key="volume">106</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">4415</infon>
      <infon key="pub-id_pmid">16326981</infon>
      <infon key="fpage">4414</infon>
      <infon key="year">2005</infon>
      <infon key="type">ref</infon>
      <offset>63407</offset>
      <text>Activating FLT3 mutations in CD4+/CD8&#8208; pediatric T&#8208;cell acute lymphoblastic leukemias</text>
    </passage>
    <passage>
      <infon key="volume">122</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">82</infon>
      <infon key="pub-id_pmid">23687089</infon>
      <infon key="fpage">74</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>63497</offset>
      <text>Prognostic relevance of integrated genetic profiling in adult T&#8208;cell acute lymphoblastic leukemia</text>
    </passage>
    <passage>
      <infon key="volume">94</infon>
      <infon key="source">Haematologica</infon>
      <infon key="lpage">134</infon>
      <infon key="pub-id_pmid">18838472</infon>
      <infon key="fpage">131</infon>
      <infon key="year">2009</infon>
      <infon key="type">ref</infon>
      <offset>63597</offset>
      <text>Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling</text>
    </passage>
    <passage>
      <infon key="volume">452</infon>
      <infon key="source">Nature</infon>
      <infon key="lpage">772</infon>
      <infon key="pub-id_pmid">18401412</infon>
      <infon key="fpage">768</infon>
      <infon key="year">2008</infon>
      <infon key="type">ref</infon>
      <offset>63691</offset>
      <text>Adult T&#8208;cell progenitors retain myeloid potential</text>
    </passage>
    <passage>
      <infon key="volume">119</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">6208</infon>
      <infon key="pub-id_pmid">22286199</infon>
      <infon key="fpage">6198</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>63743</offset>
      <text>Acute myeloid leukemia stem cells and CD33&#8208;targeted immunotherapy</text>
    </passage>
    <passage>
      <infon key="volume">24</infon>
      <infon key="source">Leukemia</infon>
      <infon key="lpage">1851</infon>
      <infon key="pub-id_pmid">20844566</infon>
      <infon key="fpage">1844</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>63811</offset>
      <text>Mixed&#8208;phenotype acute leukemia: historical overview and a new definition</text>
    </passage>
    <passage>
      <infon key="volume">20</infon>
      <infon key="source">Genes Dev</infon>
      <infon key="lpage">2109</infon>
      <infon key="pub-id_pmid">16847353</infon>
      <infon key="fpage">2096</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>63886</offset>
      <text>c&#8208;Myc is an important direct target of Notch1 in T&#8208;cell acute lymphoblastic leukemia/lymphoma</text>
    </passage>
    <passage>
      <infon key="volume">481</infon>
      <infon key="source">Nature</infon>
      <infon key="lpage">163</infon>
      <infon key="pub-id_pmid">22237106</infon>
      <infon key="fpage">157</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>63984</offset>
      <text>The genetic basis of early T&#8208;cell precursor acute lymphoblastic leukaemia</text>
    </passage>
  </document>
</collection>
